Reduce Environmental Impact of Cannabinoid Production Through Biosynthesis


In a recent article, “Reduce Environmental Impact of Cannabinoid Production Through Biosynthesis,” published in Cannabis Industry Journal, Maxim Mikheev highlighted a few significant differences between cannabinoids production through biosynthesis and conventional cultivation method. Maxim Mikheev explained why the biosynthesis method is more environmentally sustainable than commercial-scale cultivation.

The immense popularity of cannabinoids —the molecules found in the cannabis plant— has paved its way toward the pharmaceuticals, cosmetic, food, and beverage industries. Veterinary uses for cannabinoids are also prevailing. Advanced research has found new and potent cannabis compounds that are attracting customer’s attraction. This increased demand asks for less-time consuming, environment-friendly and cheap cannabinoids. Max explained two methods of cannabis production: biosynthesis and natural cultivation.

The traditional method of harvesting cannabinoids costs billions of dollars each year.  The conventional process of growth, harvest, extraction, and purification is unable to provide enough quantity of rare cannabinoids due to traces of these compounds in the plant. Besides, the traditional methods “require hundreds of acres of land, thousands of pounds of fertilizer, thousands of gallons of water and thousands of man-hours” that can have a tremendous environmental footprint. Despite this hard work, the final product may have contaminants and toxins.

According to Maxim, “Biosynthesis is the production of the desired compound through the natural means of an organism’s biological processes.” BioMedican has developed this unique environment-friendly approach to yield rare cannabinoids. Compared to conventional methods, this process requires 90% less resources. The end product is environmentally sustainable, pharmaceutical-grade, organic, and non-GMO with 70-90% lower cost than cultivation through plants.

Abrupt climate changes increased the demand for environment-friendly and cheap cannabis compounds. BioMedican noticed this demand and developed a unique biosynthesis method. We invite you to read our advanced biosynthesis approach towards rare cannabinoids and partner with us to leave an impact on this booming cannabis industry.


Saba IqbalAuthor posts

Dr. Saba Iqbal is a contributing writer for BioMedican. She's a clinical pharmacist turned writer. Dr. Saba's education includes a doctoral degree in pharmacy (Pharm D) from the University of Sargodha, Pakistan. In search of a career that would take advantage of her medical and pharmaceutical skills, Dr. Saba found medical writing – a career path a few medical students consider. In her journey "from a medical bench to pen," she has worked with several startups for many years managing content on biotech products, pharmaceuticals, drugs, devices, and techniques. While keeping up with the latest trends in medical writing, she aims to use her writing skills to clearly communicate complex scientific, medical, and health information to the potential investor and general audience.

Comments are disabled.